Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Assets (2016 - 2026)

Heron Therapeutics filings provide 16 years of Current Assets readings, the most recent being $229.0 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 7.58% to $229.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $229.0 million, a 7.58% increase, with the full-year FY2025 number at $238.1 million, up 13.9% from a year prior.
  • Current Assets hit $229.0 million in Q1 2026 for Heron Therapeutics, down from $238.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $238.1 million in Q4 2025 to a low of $165.3 million in Q2 2023.
  • Median Current Assets over the past 5 years was $205.4 million (2022), compared with a mean of $204.3 million.
  • Biggest five-year swings in Current Assets: tumbled 47.06% in 2022 and later rose 17.53% in 2025.
  • Heron Therapeutics' Current Assets stood at $205.4 million in 2022, then fell by 8.11% to $188.8 million in 2023, then grew by 10.72% to $209.0 million in 2024, then rose by 13.9% to $238.1 million in 2025, then dropped by 3.81% to $229.0 million in 2026.
  • The last three reported values for Current Assets were $229.0 million (Q1 2026), $238.1 million (Q4 2025), and $229.4 million (Q3 2025) per Business Quant data.